Lymphatic mapping and sentinel node biopsy in breast cancer

British Journal of Surgery

Volumn 85, Issue 10, 1998, Pages 1347-1356

  Mcintosh, S A ^a   Purushotham, A D ^a,b  

^a WESTERN INFIRMARY   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

TECHNETIUM SULFUR COLLOID TC 99M;

ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER RECURRENCE; CANCER STAGING; DATA BASE; HUMAN; LYMPH NODE BIOPSY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPHOSCINTIGRAPHY; MEDICAL LITERATURE; MORBIDITY; PRIORITY JOURNAL; RELIABILITY; REPRODUCIBILITY;

AXILLA; BIOPSY; BREAST NEOPLASMS; FEMALE; HUMANS; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; NEOPLASM STAGING;

EID: 0031719867     PISSN: 00071323     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2168.1998.00934.x     Document Type: Article

References (126)

1. Parkin DM, Muir CS, Whelan SL, Gao Y-T, Ferlay J, Powell J. Cancer incidence in five continents. IARC Sci Publ 1992; 773: 809.
2. Cady B. The need to reexamine axillary lymph node dissection in invasive breast cancer. Cancer 1994; 73: 505-8.
3. Carter CL, Allen C, Henson DE. Relation of tumour size, lymph node status, and survival in 24 740 breast cancer cases. Cancer 1989; 63: 181-7.
4. Walls J, Boggis CRM, Wilson M, Asbury DL, Roberts JV, Bundred NJ et al. Treatment of the axilla in patients with screen-detected breast cancer. Br J Surg 1993; 80: 436-8.
5. 1 carcinoma of the breast. J Am Coll Surg 1996; 183: 185-9.
6. Fisher B, Slack NH, Ausman RK, Bross IDJ. Location of breast carcinoma and prognosis. Surg Gynecol Obstet 1969; 129: 705-16.
7. Fisher B, Bauer M, Wickerham L, Redmond CK, Fisher ER. Relation of number of positive nodes to the prognosis of patients with primary breast cancer. An NSABP update. Cancer 1983; 52: 1551-7.
8. Graversen HP, Blichert-Toft M, Andersen JA, Zedeler K. Breast cancer: risk of axillary recurrence in node-negative patients following partial dissection of the axilla. Eur J Surg Oncol 1988; 14: 407-12.
9. Gateley CA, Mansel RE, Owen A, Redford J, Sellwood RA, Howell A. Treatment of the axilla in operable breast cancer. Br J Surg 1991; 78: 750 (Abstract).
10. Fisher B, Redmond C, Fisher ER, Bauer M, Wolmark N, Wickerham L et al. Ten-year results of a randomised clinical trial comparing radical mastectomy and total mastectomy with or without radiation. N Engl J Med 1985; 312: 674-81.
11. Fisher B, Montague E, Redmond C, Barton B, Borland D, Fisher ER et al. Comparison of radical mastectomy with alternative treatments for primary breast cancer. Cancer 1977; 39: 2827-39.
12. Fisher B, Wolmark N, Bauer M, Redmond C, Gebhardt M. The accuracy of clinical nodal staging and of limited axillary dissection as a determinant of histological nodal status in carcinoma of the breast. Surg Gynecol Obstet 1981; 152: 765-72.
13. Benson EA, Thorogood J. The effect of surgical technique on local recurrence rates following mastectomy. Eur J Surg Oncol 1986; 12: 267-71.
14. Langlands AO, Prescott RJ, Hamilton T. A clinical trial in the management of operable cancer of the breast. Br J Surg 1980; 67: 170-4.
15. Delouche G, Bachelot F, Premont M, Kurtz JM. Conservation treatment of early breast cancer: long term results and complications. Int J Radiat Oncol Biol Phys 1987; 13: 29-34.
16. Kissin MW, Thompson EM, Price AB, Slavin G, Kark AE. The inadequacy of axillary sampling in breast cancer. Lancet 1982; i: 1210-11.
17. Mathiesen O, Carl J, Bonderup O, Panduro J. Axillary sampling and the risk of erroneous staging of breast cancer. Acta Oncol 1990; 29: 721-5.
18. Davies GC, Millis RR, Hayward JL. Assessment of axillary lymph node status. Ann Surg 1980; 192: 148-51.
19. Forrest APM, Stewart HJ, Roberts MM, Steele RJC. Simple mastectomy and axillary node sampling (pectoral node biopsy) in the management of primary breast cancer. Ann Surg 1982; 196: 371-7.
20. Forrest APM, Everington D, McDonald CC, Steele RJC, Chetty U, Stewart HJ. The Edinburgh randomized trial of axillary sampling or clearance after mastectomy. Br J Surg 1995; 82: 1504-8.
21. Chetty U, Jack W, Dillon P, Tyler C, Prescott R. Axillary surgery in patients with breast cancer being treated by breast conservation: a randomised trial of node sampling and axillary clearance. Breast 1997; 6: 226 (Abstract).
22. Steele RJC, Forrest APM, Gibson T, Stewart HJ, Chetty U. The efficacy of lower axillary sampling in obtaining lymph node status in breast cancer: a controlled randomized trial. Br J Surg 1985; 72: 368-9.
23. Axelsson CK, Mouridsen HT, Zedeler K. Axillary dissection of level I and II lymph nodes is important in breast cancer classification. Eur J Cancer 1992; 28A: 1415-18.
24. Cady B. Lymph node metastases. Indicators but not governors of survival. Arch Surg 1984; 119: 1067-72.
25. Harris JR, Osteen RT. Patients with early breast cancer benefit from effective axillary treatment. Breast Cancer Res Treat 1985; 5: 17-21.
26. Recht A, Houlihan MJ. Axillary lymph nodes and breast cancer. Cancer 1995; 76: 1491-512.
27. Ivens D, Hoe AL, Podd TJ, Hamilton CR, Taylor I, Royle GT. Assessment of morbidity from complete axillary dissection. Br J Cancer 1992; 66: 136-8.
28. Swedborg I, Wallgren A. The effect of pre- and postmastectomy radiotherapy on the degree of edema, shoulder-joint mobility and gripping force. Cancer 1981; 47: 877-81.
29. Kissin MW, della Rovere GO, Easton D, Westbury G. Risk of lymphoedema following the treatment of breast cancer. Br J Surg 1986; 73: 580-4.
30. Romsdahl MM, Montague ED, Ames FC, Richards PC, Schell SR. Conservation surgery and irradiation as treatment for early breast cancer. Arch Surg 1983; 118: 521-8.
31. Aitken RJ, Gaze MN, Rodger A, Chetty U, Forrest APM. Arm morbidity within a trial of mastectomy and either nodal sample with selective radiotherapy or axillary clearance. Br J Surg 1989; 76: 568-71.
32. Lin PP, Allison DC, Wainstock J, Miller KD, Dooley WC, Friedman N et al. Impact of axillary lymph node dissection on the therapy of breast cancer patients. J Clin Oncol 1993; 11: 1536-44.
33. Tobin MB, Lacey HJ, Meyer L, Mortimer PS. The psychological morbidity of breast cancer-related arm swelling. Cancer 1993; 72: 3248-52.
34. Stewart FW, Treves N. Lymphangiosarcoma in postmastectomy oedema. Cancer 1948; 1: 64-81.
35. Vecht CJ, Van de Brand HJ, Wajer OJM. Post-axillary dissection pain in breast cancer due to a lesion of the intercostobrachial nerve. Pain 1989; 38: 171-6.
36. Tadych K, Donegan WL. Postmastectomy seromas and wound drainage. Surg Gynecol Obstet 1987; 165: 483-7.
37. Somers RG, Jablon LK, Kaplan MJ, Sandler GL, Rosenblatt NK. The use of closed suction drainage after lumpectomy and axillary node dissection for breast cancer. Ann Surg 1992; 215: 146-9.
38. Dawson I, Stam L, Heslinga JM, Kalsbeek HL. Effect of shoulder immobilization on wound seroma and shoulder dysfunction following modified radical mastectomy: a randomized prospective clinical trial. Br J Surg 1989; 76: 311-12.
39. Siegel BM, Mayzel KA, Love SM. Level I and II axillary dissection in the treatment of early-stage breast cancer. Arch Surg 1990; 125: 1144-7.
40. Sacre RA. Clinical evaluation of axillar lymph nodes compared to surgical and pathological findings. Eur J Surg Oncol 1986; 12: 169-73.
41. Bruneton JN, Caramella E, Hery M, Aubanel D, Manzino JJ, Picard JL. Axillary lymph node metastases in breast cancer: preoperative detection with US. Radiology 1986; 158: 325-6.
42. Isaacs RJ, Ford JM, Allan SG, Forgeson GV, Gallagher S. Role of computed tomography in the staging of primary breast cancer. Br J Surg 1993; 80: 1137.
43. Mumtaz H, Hall-Craggs MA, Davidson T, Walmsley K, Thurell W, Kissin MW et al. Staging of symptomatic primary breast cancer with MR imaging. AJR Am J Roentgenol 1997; 169: 417-24.
44. Wahl RL, Cody RL, Hutchins GD, Mudgett EE. Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabelled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 1991; 179: 765-70.
45. Nieweg OE, Kim EE, Wong W-H, Broussard WF, Singletary SE, Hortobagyi GN et al. Positron emission tomography with fluorine-18-deoxyglucose in the detection and staging of breast cancer. Cancer 1993; 71: 3920-5.
46. Crippa F, Agresti R, Seregni E, Greco M, Pascali C, Bogni A et al. Prospective evaluation of fluorine-18-FDG PET in presurgical staging of the axilla in breast cancer. J Nucl Med 1998; 39: 4-8.
47. Cabanas RM. An approach for the treatment of penile carcinoma. Cancer 1977; 39: 456-66.
48. Morton DL, Wen D-R, Wong JH, Economou JS, Cagle LA, Storm FK et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992; 127: 392-9.
49. Wong JH, Cagle LA, Morton DL. Lymphatic drainage of skin to a sentinel lymph node in a feline model. Ann Surg 1991; 214: 637-41.
50. Hirsch JI, Tisnado J, Cho S-R, Beachley MC. Use of isosulfan blue for identification of lymphatic vessels: experimental and clinical evidence. AJR Am J Roentgenol 1982; 139: 1061-4.
51. Reintgen D, Cruse CW, Wells K, Berman C, Fenske N, Glass F et al. The orderly progression of melanoma nodal metastases. Ann Surg 1994; 220: 759-67.
52. Albertini JJ, Cruse CW, Rapaport D, Wells K, Ross M, DeConti R et al. Intraoperative radiolymphoscintigraphy improves sentinel node identification for patients with melanoma. Ann Surg 1996; 223: 217-24.
53. Pijpers R, Collet GJ, Meijer S, Hoekstra OS. The impact of dynamic lymphoscintigraphy and gamma probe guidance on sentinel node biopsy in melanoma. Eur J Nucl Med 1995; 22: 1238-41.
54. Krag DN, Meijer SJ, Weaver DL, Loggie BW, Harlow SP, Tanabe KK et al. Minimal-access surgery for staging of malignant melanoma. Arch Surg 1995; 130: 654-8.
55. Alex JC, Weaver DL, Fairbank JT, Rankin BS, Krag DN. Gamma probe guided lymph node localisation in malignant melanoma. Surg Oncol 1993; 2: 303-8.
56. Uren RF, Howman-Giles RB, Shaw HM, Thompson JF, McCarthy WH. Lymphoscintigraphy in high-risk melanoma of the trunk: predicting draining node groups, defining lymphatic channels and locating the sentinel node. J Nucl Med 1993; 34: 1435-40.
57. van der Veen H, Hoekstra OS, Paul MA, Cuesta MA, Meijer S. Gamma probe-guided sentinel node biopsy to select patients with melanoma for lymphadenectomy. Br J Surg 1994; 81: 1769-70.
58. Alex JC, Krag DN. Gamma probe guided localisation of lymph nodes. Surg Oncol 1993; 2: 137-43.
59. Giuliano AE, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg 1994; 220: 391-401.
60. Giuliano AE. Sentinel lymphadenectomy in primary breast carcinoma: an alternative to routine axillary dissection. J Surg Oncol 1996; 62: 75-7.
61. Nieweg OE, Kapteijn BAE, Peterse JL, Rutgers EJT, Van Dongen JA, Kroon BBR. Identificatie van de schildwachtklier bij patienten met mammacarcinoom. Ned Tijdsch Geneeskd 1996; 140: 2235-9.
62. Folscher DJ, Langman G, Panieri E, Theunissen D, Dent DM. Sentinel axillary lymph node biopsy: helpful in axillary management in patients with breast cancer? Br J Surg 1997; 84: 1586 (Abstract).
63. Flett M, Stanton PD, Cooke TG. Lymphatic mapping and sentinel node biopsy in breast cancer. Br J Surg 1998; 85: 991-3.
64. Horgan K, Mancie-Jones B, Madan M, Andrew A, Quinn C. Axillary sentinel node identification in breast cancer with dye alone. Br J Surg 1998; 85(Suppl 1): 51-2 (Abstract).
65. Albertini JJ, Lyman GH, Cox C, Yeatman T, Balducci L, Ku N et al. Lymphatic mapping and sentinel node biopsy in the patient with breast cancer. JAMA 1996; 276: 1818-21
66. Krag DN, Weaver DL, Alex JC, Fairbank JT. Surgical resection and radiolocalisation of the sentinel node in breast cancer using a gamma probe. Surg Oncol 1993; 2: 335-40.
67. Veronesi U, Paganelli G, Galimberti V, Viale G, Zurrida S, Bedoni M et al. Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph nodes. Lancet 1997; 349: 1864-7.
68. Gill PG, Hall VE, Kirkwood I, Chatterton BE, Coventry B, Vernon-Roberts E. Lymphoscintigraphy for locating the sentinel lymph node in patients with breast cancer. Breast 1997; 6: 225 (Abstract).
69. Borgstein PJ, Pijpers R, Comans EF, van Diest PJ, Boom RP, Meijer S. Sentinel lymph node biopsy in breast cancer: guidelines and pitfalls of lymphoscintigraphy and gamma probe detection. J Am Coll Surg 1998; 186: 275-83.
70. Roumen RMH, Valkenburg JGM, Geuskens LM. Lymphoscintigraphy and feasibility of sentinel node biopsy in 83 patients with primary breast cancer. Eur J Surg Oncol 1997; 23:495-502.
71. Ege GN. Lymphoscintigraphy - techniques and applications in the management of breast carcinoma. Semin Nucl Med 1983; 13: 26-34.
72. McLean RG, Ege GN. Prognostic value of axillary lymphoscintigraphy in breast carcinoma patients. J Nucl Med 1986; 27: 1116-24.
73. Ege GN, Clark RM. Internal mammary lymphoscintigraphy in the conservative management of breast carcinoma: an update and recommendations for a new TNM staging. Clin Radiol 1985; 36: 469-72.
74. Kaplan WD, Andersen JW, Siddon RL, Connolly BT. McCormick CA, Laffin SM et al. The three-dimensional localisation of internal mammary lymph nodes by radionuclide lymphoscintigraphy. J Nucl Med 1988; 29: 473-8.
75. Bourgeois P, Fruhling J, Henry J. Postoperative axillary lymphoscintigraphy in the management of breast cancer. Int J Radiat Oncol Biol Phys 1983; 9: 29-32.
76. Yip T-CK, Ege GN. Determination of depth distribution of internal mammary lymph nodes on lateral lymphoscintigraphy. Clin Radiol 1985; 36: 149-52.
77. Uren RF, Howman-Giles RB, Thompson JF, Malouf D, Ramsey-Stewart G, Niesche FW et al. Mammary lymphoscintigraphy in breast cancer. J Nucl Med 1997; 36: 1775-80.
78. Pijpers R, Meijer S, Hoekstra OS, Collet GJ, Comans EFI, Boom RPA et al. Impact of lymphoscintigraphy on sentinel node identification with technetium-99m-colloidal albumin in breast cancer. J Nucl Med 1997; 38: 366-8.
79. Offodile R, Hoh C, Barsky SH, Nelson SD, Elashoff R, Eilber FR et al. Minimally invasive breast carcinoma staging using lymphatic mapping with radiolabeled dextran. Cancer 1998; 82: 1704-8.
80. de Vries J, Schraffordt Koops H, Piers DA, Tiebosch ATMG, Nieweg OE. Introduction of sentinel node biopsy in breast cancer using lymphoscintigraphy and blue dye. Breast 1997; 6: 332-3 (Abstract).
81. O'Hea BJ, Hill ADK, El-Shirbiny AM, Yeh SDJ, Rosen PP, Coit DG et al. Sentinel lymph node biopsy in breast cancer: initial experience at Memorial Sloan-Kettering Cancer Center. J Am Coll Surg 1998; 186: 423-7.
82. Cox CE, Pendas S, Cox JM, Joseph E, Shons AR. Yeatman T et al. Guidelines for sentinel node biopsy and lymphatic mapping of patients with breast cancer. Ann Surg 1998; 227: 645-53.
83. Turner RR, Ollila DW, Krasne DL, Giuliano AE. Histopathologic validation of the sentinel node hypothesis for breast cancer. Ann Surg 1997; 226: 271-8.
84. Veronesi U, Luini A, Galimberti V, Marchini S, Sacchim V, Rilke F. Extent of metastatic involvement in 1446 cases of breast cancer. Eur J Surg Oncol 1990; 16: 127-33.
85. Rosen PP, Lesser ML, Kinne DW, Beattie EJ. Discontinuous or 'skip' metastases in breast carcinoma. Analysis of 1228 axillary dissections. Ann Surg 1983; 197: 276-83.
86. Veronesi U, Rilke F, Luini A, Sacchini V, Galimberti V, Campa T et al. Distribution of axillary node metastases by level of invasion. An analysis of 539 cases. Cancer 1987; 59: 682-7.
87. Boova R, Bonanni R, Rosato F. Patterns of axillary nodal involvement in breast cancer: predictability of level I dissection. Ann Surg 1982; 196: 642-4.
88. Kitchen P, McLennan R, Mursell A. Node-positive breast cancer: a comparison of clinical and pathological findings and assessment of axillary clearance. Aust N Z J Surg 1980; 50: 580-3.
89. Pigott J, Nichols R, Maddox W, Balch C. Metastases to the upper levels of the axillary nodes in carcinoma of the breast and its implications for nodal sampling procedures. Surg Gynecol Obstet 1984; 158: 255-9.
90. Saphir O, Amromin GD. Obscure axillary lymph node metastasis in carcinoma of the breast. Cancer 1948; 1: 238-41.
91. Pickren JW. Significance of occult metastases A study of breast cancer. Cancer 1961; 14: 1266-71.
92. Fisher ER, Swamidoss S, Lee CH, Rockette H, Redmond C, Fisher B. Detection and significance of occult axillary node metastases in patients with invasive breast cancer. Cancer 1978; 42: 2025-31.
93. Friedman S, Bertin F, Mouriesse H, Benchabat A, Genin J, Sarrazin D et al. Importance of tumour cells in axillary node sinus margins ('clandestine' metastases) discovered by serial sectioning in operable breast carcinoma. Acta Oncol 1988; 27: 483-7.
94. International (Ludwig) Breast Cancer Study Group. Prognostic importance of occult axillary lymph node micrometastases from breast cancers. Lancet 1990; 335: 1565-8.
95. Wilkinson EJ, Hause LL, Hoffman RG, Kuzma JF, Rothwell DJ, Donegan WL et al. Occult axillary lymph node metastases in invasive breast carcinoma: characteristics of the primary tumour and significance of the metastases. Pathology Annual 1982; 17: 67-91.
96. Byrne J, Waldron R, McAvinchey D, Dervan P. The use of monoclonal antibodies for the histopathological detection of mammary axillary micrometastases. Eur J Surg Oncol 1987; 13: 409-11.
97. Wells CA, Heryet A, Brochier J, Gatter KC, Mason DY. The immunocytochemical detection of axillary micrometastases in breast cancer. Br J Cancer 1984; 50: 193-7.
98. Bussolati G, Gugliotta P, Morra I, Pietribiasi F, Berardengo E. The immunohistochemical detection of lymph node metastases from infiltrating lobular carcinoma of the breast. Br J Cancer 1986; 54: 631-6.
99. Trojani M, de Mascarel I, Bonichon F, Coindre JM, Delsol D. Micrometastases to axillary lymph nodes from carcinoma of breast: detection by immunohistochemistry and prognostic significance. Br J Cancer 1987; 55: 303-6.
100. Nasser IA, Lee AKC, Bosari S, Saganich R, Heatley G, Silverman ML. Occult axillary node micrometastases in 'node-negative' breast carcinoma. Hum Pathol 1993; 24: 950-7.
101. Hainsworth PJ, Tjandra JJ, Stillwell RG, Machet D, Henderson MA, Rennie GC et al. Detection and significance of occult metastases in node-negative breast cancer. Br J Surg 1993; 80: 459-63.
102. McGuckin MA, Cummings MC, Walsh MD, Hohn BG, Bennett IC, Wright RG. Occult axillary node metastases in breast cancer: their detection and prognostic significance. Br J Cancer 1996; 73: 88-95.
103. Noguchi S, Aihara T, Nakamori S, Motomura K, Inaji H, Imaoka S et al. The detection of breast cancer micrometastases in axillary lymph nodes by means of reverse transcriptase polymerase chain reaction. Cancer 1994; 74: 1595-600.
104. Mori M, Mimori K, Inoue H, Barnard GF, Tsuji K, Nanbara S et al. Detection of cancer micrometastases in lymph nodes by reverse transcriptase polymerase chain reaction. Cancer Res 1995; 55: 3417-20.
105. Noguchi S, Aihara T, Motomura K, Inaji H, Imaoka S, Koyama H. Detection of breast cancer micrometastases in axillary lymph nodes by means of reverse transcriptase polymerase chain reaction. Am J Pathol 1946; 148: 649-56.
106. Huvos AG, Hutter RVP, Berg JW. Significance of axillary macrometastases and micrometastases in breast cancer. Ann Surg 1971; 173: 44-6.
107. Attiyeh FF, Jensen M, Huvos AG, Fracchia A. Axillary micrometastasis and macrometastasis in carcinoma of the breast. Surg Gynecol Obstet 1977; 144: 839-42.
108. de Mascarel I, Bonichon F, Coindre JM, Trojani M. Prognostic significance of breast cancer axillary lymph node micrometastases assessed by two special techniques: reevaluation with longer follow-up. Br J Cancer 1992; 66: 523-7.
109. 0 stage I breast carcinoma: a 20-year follow up study. J Clin Oncol 1991; 9: 1650-61.
110. Dowlatshahi K, Fan M, Snider HC, Habib FA. Lymph node micrometastases from breast carcinoma. Cancer 1997; 80: 1188-97.
111. Giuliano AE, Dale PS, Turner RR, Morton DL, Evans SW, Krasne DL. Improved axillary staging of breast cancer with sentinel lymphadenectomy. Ann Surg 1995; 222: 394-401.
112. Veronesi U, Valagussa P. Inefficacy of internal mammary nodes dissection in breast cancer surgery. Cancer 1981; 47: 170-5.
113. Veronesi U, Cascinelli N, Greco M, Bufalino R, Morabito A, Galluzzo D et al. Prognosis of breast cancer patients after mastectomy and dissection of internal mammary nodes. Ann Surg 1985; 202: 702-7.
114. Veronesi U, Cascinelli N, Bufalino R, Morabito A, Greco M, Galluzzo D et al. Risk of internal mammary lymph node metastases and its relevance on prognosis of breast cancer patients. Ann Surg 1983; 198: 681-4.
115. Lacour J, Bucalossi P, Cacers E, Jacobelli G, Koszarowski T, Le M et al. Radical mastectomy versus radical mastectomy plus internal mammary dissection. Cancer 1976; 37: 206-14.
116. Giuliano AE. Invited commentary. Ann Surg 1997; 226: 277-8.
117. Bergqvist L, Strand S-E, Persson BRR. Particle sizing and biokinetics of interstitial lymphoscintigraphic agents. Semin Nucl Med 1983; 13: 9-19.
118. Henze E, Schelbert HR, Collins JD, Najafi A, Barrio JR, Bennett LR. Lymphoscintigraphy with Tc-99m-labeled dextran. J Nucl Med 1982; 23: 923-9.
119. Taylor A, Murray D, Herda S, Vansant J, Alazraki N. Dynamic lymphoscintigraphy to identify the sentinel and satellite nodes. Clin Nucl Med 1996; 21: 755-8.
120. Grant RN, Tabah EJ, Adair FE. The surgical significance of the subareolar plexus in cancer of the breast. Surgery 1959; 33: 71-8.
121. Borgstein PJ, Meijer S, Pijpers R. Intradermal blue dye to identify sentinel lymph node in breast cancer. Lancet 1997; 349: 1668-9.
122. Turner-Warwick RT. The lymphatics of the breast. Br J Surg 1959; 46: 574-82.
123. Vendrell-Torne E, Setoain-Quinquer J, Domenech-Torne FM. Study of normal lymphatic mammary drainage using radioactive isotopes. J Nucl Med 1972; 13: 801-6.
124. Dixon JM, Mamman U, Thomas J. Intraoperative frozen section of axillary lymph nodes: a study of its accuracy. Br J Surg 1998; 85(Suppl 1): 69 (Abstract).
125. 1 breast carcinoma. Cancer 1997; 79: 1918-22.
126. Veronesi U. Sentinel-node biopsy in breast cancer (reply). Lancet 1997; 350: 809.